Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Nephrotoxicity: full-pipeline trial registry
1 of 3 indexed Nephrotoxicity trials are currently recruiting.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Nephrotoxicity: 3 US clinical trials tracked, 1 recruiting.
Nephrotoxicity is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Matrix Biomed, running 1 of these trials.
Enrollment posture brief
Registry condition nephrotoxicity
OPEN 1 | RECR 33% | LATE 1 | EARLY 1 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Nephrotoxicity lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Nephrotoxicity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Nephrotoxicity is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
Matrix Biomed
NCT03480971
Cisplatin Disposition and Kidney Injury
University of Colorado, Denver
NCT03817970
Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin to Predict AKI in the NICU
University of Alabama at Birmingham
NCT04354467
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Nephrotoxicity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Nephrotoxicity trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Nephrotoxicity page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Nephrotoxicity trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Matrix Biomed sponsors the most Nephrotoxicity trials on record, review their full trial history before evaluating a specific study. See Matrix Biomed's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Nephrotoxicity condition card totals 3 registered trials; most-linked intervention urine neutrophil gelatinase -associated lipocalin; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.